Department of Orthopedic, The 908th Hospital of Chinese People's Liberation Army Joint Logistic Support Force, Nanchang, 330002, Jiangxi, China.
J Orthop Surg Res. 2024 Nov 7;19(1):733. doi: 10.1186/s13018-024-05210-z.
Residual low back and leg pain can occur after percutaneous endoscopic interlaminar discectomy (PEID) and compromise early surgical outcomes. This study aimed to determine the efficacy of combining dexamethasone with vitamin B12 (VB12) via epidural injection in improving the symptoms of low back and leg pain after PEID, and the underlying mechanism of action.
Patients who underwent PEID for lumbar disc herniation (LDH) were enrolled and randomly assigned to the single surgery (SS) group, where disc removal was performed via PEID alone, or the combined treatment (CT) group, which received epidural injections of dexamethasone and VB12 alongside surgery. The outcome measures were the Visual Analog Scale (VAS), Japanese Orthopaedic Association (JOA) score, Oswestry Disability Index (ODI), serum inflammatory factor expression, adverse surgical events, duration of postoperative hospitalization, and modified MacNab criteria.
Compared with the SS group, the CT group exhibited lower VAS scores for low back and leg pain at 1, 3, and 7 days post-surgery (P < 0.05). JOA and ODI scores were significantly improved in the CT group than in the SS group 7 days post-surgery (P < 0.05); however, no significant differences were observed at other time points. Serum inflammatory factors were lower in the CT group than in the SS group 3 days post-surgery (P < 0.05). The duration of postoperative hospitalization was shorter in the CT group (P < 0.05). Both groups had similar good outcomes (89.3% vs. 92.2%, P = 0.945).
Epidural injection of dexamethasone and VB12 effectively reduces early postoperative low back and leg pain, lowers postoperative inflammatory factor expression, and improves early PEID outcomes. Its clinical adoption merits consideration.
This trial was registered with the China Clinical Trial Registration Center (Identifier: ChiCTR2400088854).
经皮内镜下腰椎间融合术(PEID)后仍会出现腰腿痛和下肢痛,影响早期手术效果。本研究旨在探讨硬膜外注射地塞米松联合维生素 B12(VB12)对改善 PEID 术后腰腿痛症状的疗效及其作用机制。
纳入行 PEID 治疗腰椎间盘突出症(LDH)的患者,随机分为单纯手术(SS)组,即单纯行 PEID 切除椎间盘;联合治疗(CT)组,手术同时行硬膜外注射地塞米松和 VB12。观察两组术后视觉模拟评分(VAS)、日本骨科协会(JOA)评分、Oswestry 功能障碍指数(ODI)、血清炎性因子表达、不良手术事件、术后住院时间及改良 MacNab 标准。
与 SS 组相比,CT 组术后 1、3、7 d 腰痛和腿痛 VAS 评分均降低(P<0.05);术后 7 d CT 组 JOA 评分、ODI 评分优于 SS 组(P<0.05),其他时间点两组间比较差异无统计学意义;术后 3 d CT 组血清炎性因子水平低于 SS 组(P<0.05);CT 组术后住院时间短于 SS 组(P<0.05)。两组术后优良率比较差异无统计学意义(89.3%比 92.2%,P=0.945)。
硬膜外注射地塞米松联合 VB12 可有效减轻术后早期腰痛和腿痛,降低术后炎性因子表达,改善早期 PEID 疗效,值得临床推广。
本研究在中国临床试验注册中心注册(注册号:ChiCTR2400088854)。